

## Submission Data File

General Information	
Form Type*	6-K
Contact Name	M2 Compliance
Contact Phone	754-243-5120
<b>Filer File Number</b>	
Filer CIK*	0001849296
Filer CCC*	*****
Confirming Copy	No
Notify via Website only	No
Return Copy	Yes
SROS*	NONE
Period*	
(End General Information)	

Document Information	
File Count*	3
Document Name 1*	form6-k.htm
Document Type 1*	6-K
<b>Document Description 1</b>	
Document Name 2*	ex99-1.htm
Document Type 2*	EX-99.1
<b>Document Description 2</b>	
Document Name 3*	ex99-1_001.jpg
Document Type 3*	GRAPHIC
<b>Document Description 3</b>	
(End Document Information)	

Notifications	
Notify via Website only	No
E-mail 1	filing@m2compliance.com
(End Notifications)	

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**August 2022**

---

**Commission File Number: 001-41386**

---

**OKYO Pharma LTD**

(Exact Name of Registrant as Specified in Its Charter)

---

**9<sup>th</sup> Floor  
107 Cheapside  
London  
EC2V 6DN**

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

## INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 30, 2022, OKYO Pharma LTD (the “Company”) issued a news service announcement in the United Kingdom announcing that OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**OKYO Pharma LTD**

Date: August 30, 2022

By: /s/ Gary Jacob

Name: Gary Jacob

Title: Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#"><u>News Service Announcement, dated August 30, 2022</u></a>

## Exhibit 99.1

**OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm**

- OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.
- Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential.
- IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 2023.
- Multibillion-dollar DED market whose medical needs remain largely unmet.
- AmbioPharm supporting OK-101 program with peptide synthesis and development.

London and New York, N.Y., and North Augusta, S.C. 30 August 2022

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, **plans a Q4 2022 IND filing for OK-101** to treat dry eye disease (DED), with AmbioPharm playing a key role in peptide manufacturing and development.

OK-101 is a lipid-peptide analog developed using a novel membrane-anchored peptide (MAP) technology. It consists of a 12 amino acid peptide sequence, a linker component, and an anchoring lipid domain. OK-101 is designed to increase the potency and combat ocular washout through the inclusion of the lipid ‘anchor’ contained in the molecule to enhance the residence time within the ocular environment. The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP. Inflammation and pain are the two main symptoms of DED, and inflammation is believed to be a major driver of the DED condition.

**OK-101 has novel speed-to-market potential** by skipping a Phase I trial as the drug is administered topically, and by designing its Phase 2 trial effectively as a Phase 3 registration trial. Additionally, animal studies have shown no adverse effects of the drug.

In Q1 2022, OKYO had a successful pre-IND meeting with the FDA and the FDA concurred with OKYO’s plan to prespecify co-primary efficacy endpoints of DED disease in the planned Phase 2 clinical trial. The Phase 2 trial, designed as effectively a Phase 3 registration trial, if successful, **would accelerate the timeline to new drug application (NDA)**.

DED remains largely a major unmet medical need as approved drugs, to date, still leave many patients unsatisfied. Consequently, there is multi-billion-dollar market potential for an effective drug with minimal side effects to treat this disease.

---

**AmbioPharm is supporting the OK-101 program with peptide synthesis and development.** A peptide contract development and manufacturing organization (CDMO) providing cGMP peptide APIs with capabilities ranging from research to commercial scales, AmbioPharm actively engages with innovative biopharmaceutical companies in developing first-in-class, best-in-class, and breakthrough peptide technologies that utilize AmbioPharm's peptide manufacturing expertise and in-depth scientific experience in novel and conventional peptide chemistry. "The OK-101 program is a perfect fit for our dynamic business model, which helps our partners by providing high quality products and services with a highly competitive cost structure," said Michael W. Pennington, Ph.D., Chief Scientific Officer of AmbioPharm Inc.

"We are absolutely delighted to have AmbioPharm, a global leader in the synthesis of peptides and peptide analogs, manufacturing our drug candidate OK-101," said Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma Ltd. "The work performed by AmbioPharm during this post-COVID 19 period to keep us on schedule with the manufacture of API went above and beyond the call of duty and was a testament to the high standards that AmbioPharm abides by."

### **About OKYO**

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) is a life sciences and biotechnology company recently listed on Nasdaq and admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc.

For further information, please visit [www.okyopharma.com/](http://www.okyopharma.com/)

### **About AmbioPharm**

AmbioPharm, a part of the Ambio Pharmaceuticals Group, is a leading and innovation-driven company specializing in the development and manufacture of peptides and peptide-related products. With a comprehensive range of services, AmbioPharm produces custom products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

Further information is available at [www.ambiopharm.com](http://www.ambiopharm.com).

---

## **Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements including with respect to the creation of a trading market for ADSs representing the Ordinary Shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including market conditions. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. . The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

## **Contacts**

### **OKYO**

Gary S. Jacob, Ph.D., Chief Executive Officer  
Phone: (212) 209-3998

### **AmbioPharm Inc.**

Mark DaFonseca, EVP, Sales & Global Business Development  
[mark.dafonseca@ambiofarm.com](mailto:mark.dafonseca@ambiofarm.com)

---